Related Experiment Video
Updated: Jun 17, 2026

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Triple reuptake inhibitors: a premise and promise
David M Marks1, Chi-Un Pae, Ashwin A Patkar
1Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA.
Abstract:
On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these drugs. Research suggests that they may have a role in treating depressive disorders, and it is plausible they may have potential efficacy in obesity, addiction, and pain syndromes. The current review describes some of the molecules in development presently and explores the research relevant to possible clinical uses for this class of medications.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Overview
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Oral Drug Delivery Systems: Continuous-Release Systems

